Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2022-07-22 Proxy Solicitation & In…
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2022-07-22 English
CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 22, 2022, for Sonoma Pharmaceuticals, Inc. The content focuses on changes in the company's board of directors and senior management, including the appointment of a new director (the CEO joining the board), amended employment agreements for the CEO and COO, bonus grants, and the departure of the CFO. There are no financial statements or detailed financial performance data presented. The primary subject is management changes and related agreements. According to the filing definitions, announcements of changes in the company's board or senior management fall under Board/Management Information (MANG). The document is not an annual or quarterly report, nor an earnings release or other financial report. Therefore, the correct classification is MANG with high confidence.
2022-07-22 English
FORM 10-K
Annual Report FY 2022
2022-07-13 English
FORM 12B-25
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the Form 10-K annual report for the period ended March 31, 2022, could not be filed on time due to the auditors requiring additional time to complete their audit. The document does not contain the actual 10-K report or any financial data, but rather is a notification about the delay in filing the 10-K. The document length is 3881 characters, which is relatively short and consistent with a notification form rather than a full report. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document notifying the SEC of a late filing, not the report itself.
2022-06-29 English
FORM 10-Q
Interim / Quarterly Report Q3 2022
2022-02-11 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes entry into material definitive agreements related to distribution and licensing, including details about terms and parties involved. There are no financial statements or detailed financial performance data included, nor is this an earnings release or annual/interim report. The document is not a proxy, voting result, or management change announcement. It is a regulatory filing to disclose significant corporate events as required by the SEC. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 5923 characters, which is sufficient for a substantive filing but it is not a full financial report or presentation.
2022-01-20 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.